Herpes Zoster Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026

Published: Mar 2022

Pages: 120

SKU: IRTNTR72716

Snapshot

The herpes zoster therapeutics market share is expected to increase by USD 4.51 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 14.67%.

This herpes zoster therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers herpes zoster therapeutics market segmentation by product (vaccination and drug therapy) and geography (North America, Europe, Asia, and ROW). The herpes zoster therapeutics market report also offers information on several market vendors, including Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG among others.

What will the Herpes Zoster Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Herpes Zoster Therapeutics Market Size for the Forecast Period and Other Important Statistics

Herpes Zoster Therapeutics Market: Key Drivers, Trends, and Challenges

The increased incidence of herpes zoster is notably driving the herpes zoster therapeutics market growth, although factors such as the weak pipeline for herpes zoster therapeutics may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the herpes zoster therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Herpes Zoster Therapeutics Market Driver

The increased incidence of herpes zoster is one of the key drivers supporting the herpes zoster therapeutics market growth. Exposure to ultraviolet radiation may suppress cell-mediated immunity, which can be a major factor responsible for the increased incidence of herpes zoster. Additionally, factors such as stress are expected to weaken the immune system of an individual. The weakened immune system further increases the risk of getting herpes zoster and other infectious diseases. Furthermore, tropical climate may be associated with the increasing incidence of shingles. Patients being treated for cancer and people with advanced HIV infection are at a greater risk of developing shingles. Thus, the increased incidence of herpes zoster across the globe is expected to drive the growth of the market during the forecast period.

Key Herpes Zoster Therapeutics Market Trend

The emerging innovative vaccines for disease management is one of the key trends contributing to the herpes zoster therapeutics market growth. Until the development of vaccines, the treatment for herpes zoster was dependent completely on drug therapies. However, vendors have been focusing on developing several new therapies for the treatment and prevention of shingles. For instance, V 212 by Merck is currently being evaluated in the Phase III stage of development for the treatment of varicella-zoster. It has been observed that the molecule can reduce the incidence of herpes zoster by 64% in immunocompromised patients. The vaccine has already completed Phase III trials in the US and some of the European and Asian countries, and it is expected to be launched in a few years. Such new vaccines are expected to have better efficacy in treating and preventing herpes zoster. They are also expected to be marketed at lower prices than the currently available ones. This, in turn, will drive the market growth during the forecast period.

Key Herpes Zoster Therapeutics Market Challenge

The weak pipeline for herpes zoster therapeutics is one of the factors hindering the herpes zoster therapeutics market growth. Despite the availability of vaccination for shingles, the worldwide acceptance of the vaccines has been varied across countries. The main reasons for the reduced acceptance of vaccines among patients include the fear of an upward shift in the peak of the age of the infection. Moreover, universal childhood varicella vaccination programs are not mandatory in most countries. Due to these factors, even though the global herpes zoster therapeutics market has huge growth potential, the realizable market for vaccines may remain low. This will make it less attractive for vaccine manufacturers. Thus, the weak pipeline for herpes zoster is expected to hinder the growth of the global herpes zoster therapeutics market during the forecast period.

This herpes zoster therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the herpes zoster therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the herpes zoster therapeutics market during the forecast period.

Who are the Major Herpes Zoster Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

This statistical study of the herpes zoster therapeutics market encompasses successful business strategies deployed by the key vendors. The herpes zoster therapeutics market is fragmented and the vendors are deploying growth strategies such as focusing on expanding their business activities in developed and rapidly emerging markets by launching products to compete in the market.

Product Insights and News

Cipla Ltd. is a public company that is headquartered in India. It is a global company that generated a revenue of $2587 million and had around 25000 employees. Its revenue from the global herpes zoster therapeutics market contributes to its overall revenues, along with its other offerings, but is not a key revenue stream for the company.
Cipla Ltd. - The company offers herpes zoster therapeutics through its ACIVIR DT tablets (Aciclovir).

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The herpes zoster therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Herpes Zoster Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the herpes zoster therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

Research and development (R&D) and drug discovery:
Integration and product development
Manufacturing
Outbound logistics
Marketing and sales
Support activities
Innovation

The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.

Which are the Key Regions for Herpes Zoster Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for herpes zoster therapeutics market in North America. Market growth in this region will be faster than the growth of the market in ROW.

The sales of drugs and vaccines used in the treatment/prophylaxis of herpes zoster will facilitate the herpes zoster therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The increase in the number of COVID-19 cases across the region led people to delay elective medical procedures and treatment, including that for herpes zoster, to prevent the risk of contracting COVID-19. However, after the lifting of lockdown restrictions, the increase in the number of new and rescheduled medical procedures and treatment, including for herpes zoster, has raised the demand for herpes zoster treatment. Hence, the herpes zoster therapeutics market is expected to lead to the recovery and growth of the regional market during the forecast period.

What are the Revenue-generating Product Segments in the Herpes Zoster Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The herpes zoster therapeutics market share growth by the vaccination segment will be significant during the forecast period. Vaccines are among the most important biologic therapies that help in the prevention of various disease outbreaks. The importance of vaccines comes from the fact that they are able to provide active immunization, wherein dead or live microbial antigens are administered to individuals before they are naturally infected by the antigen. After immunization, if the person gets infected by that antigen, there will be sufficient antibodies present in the body, which will rapidly eliminate that antigen. Such effective application of vaccines will positively impact the segment growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the herpes zoster therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in:

Herpes Treatment market - The market share is expected to increase by USD 723.04 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 3.4%.

Herpes Zoster Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 14.67%
Market growth 2022-2026	$ 4.51 billion
Market structure	Fragmented
YoY growth (%)	10.40
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 41%
Key consumer countries	US, Germany, China, Canada, and UK
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Herpes Zoster Therapeutics Market Report?

CAGR of the market during the forecast period 2022-2026
Detailed information on factors that will drive herpes zoster therapeutics market growth during the next five years
Precise estimation of the herpes zoster therapeutics market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the herpes zoster therapeutics industry across North America, Europe, Asia, and ROW
A thorough analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of herpes zoster therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

1. Executive Summary

1.1 Market Overview

Exhibit 01: Key Finding 1

Exhibit 02: Key Finding 2

Exhibit 03: Key Finding 3

Exhibit 04: Key Finding 5

Exhibit 05: Key Finding 6

Exhibit 06: Key Finding 7

Exhibit 07: Key Finding 8

2. Market Landscape

2.1 Market ecosystem

Exhibit 08: Parent market

Exhibit 09: Market characteristics

2.2 Value chain analysis

Exhibit 10: Value chain analysis: Pharmaceuticals

3. Market Sizing

3.1 Market segment analysis

Exhibit 11: Market segments

3.2 Market size 2021

3.3 Market definition

Exhibit 12: Offerings of vendors included in the market definition

3.4 Market outlook: Forecast for 2021 - 2026

Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)

Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)

4. Five Forces Analysis

4.1 Five Forces Summary

Exhibit 15: Five forces analysis 2021 & 2026

4.2 Bargaining power of buyers

Exhibit 16: Bargaining power of buyers

4.3 Bargaining power of suppliers

Exhibit 17: Bargaining power of suppliers

4.4 Threat of new entrants

Exhibit 18: Threat of new entrants

4.5 Threat of substitutes

Exhibit 19: Threat of substitutes

4.6 Threat of rivalry

Exhibit 20: Threat of rivalry

4.7 Market condition

Exhibit 21: Market condition - Five forces 2021

5 Market Segmentation by Product

5.1 Market segments

Exhibit 22: Product - Market share 2021-2026 (%)

5.2 Comparison by Product

Exhibit 23: Comparison by Product

5.3 Vaccination - Market size and forecast 2021-2026

Exhibit 24: Vaccination - Market size and forecast 2021-2026 ($ million)

Exhibit 25: Vaccination - Year-over-year growth 2021-2026 (%)

5.4 Drug therapy - Market size and forecast 2021-2026

Exhibit 26: Drug therapy - Market size and forecast 2021-2026 ($ million)

Exhibit 27: Drug therapy - Year-over-year growth 2021-2026 (%)

5.5 Market opportunity by Product

Exhibit 28: Market opportunity by Product

6. Customer landscape

6.1 Overview

Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

Exhibit 29: ?Customer landscape?

7. Geographic Landscape

7.1 Geographic segmentation

Exhibit 30: Market share by geography 2021-2026 (%)

7.2 Geographic comparison

Exhibit 31: Geographic comparison

7.3 North America - Market size and forecast 2021-2026

Exhibit 32: North America - Market size and forecast 2021-2026 ($ million)

Exhibit 33: North America - Year-over-year growth 2021-2026 (%)

7.4 Europe - Market size and forecast 2021-2026

Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)

Exhibit 35: Europe - Year-over-year growth 2021-2026 (%)

7.5 Asia - Market size and forecast 2021-2026

Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)

Exhibit 37: Asia - Year-over-year growth 2021-2026 (%)

7.6 ROW - Market size and forecast 2021-2026

Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)

Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)

7.7 Key leading countries

Exhibit 40: Key leading countries

7.8 Market opportunity by geography

Exhibit 41: Market opportunity by geography

8. Drivers, Challenges, and Trends

8.1 Market drivers

8.1.1 Increased incidence of herpes zoster

8.1.2 Rising geriatric population

8.1.3 Favorable reimbursement policies for medications, including vaccines

8.2 Market challenges

8.2.1 Weak pipeline for herpes zoster therapeutics

8.2.2 High generic influx of generics

8.2.3 Patient propensity toward substitutes

Exhibit 42: Impact of drivers and challenges

8.3 Market trends

8.3.1 Emerging innovative vaccines for disease management

8.3.2 Vaccination programs and initiatives providing free vaccines

8.3.3 Expanding research

9. Vendor Landscape

9.1 Overview

Exhibit 43: Vendor landscape

The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.

9.2 Landscape disruption

Exhibit 44: ?Landscape disruption?

Exhibit 45: Industry risks

10. Vendor Analysis

10.1 Vendors covered

Exhibit 46: Vendors covered

10.2 Market positioning of vendors

Exhibit 47: ?Market positioning of vendors?

10.3 Abbott Laboratories

Exhibit 48: Abbott Laboratories - Overview

Exhibit 49: Abbott Laboratories - Business segments

Exhibit 50: Abbott Laboratories - Key news

Exhibit 51: Abbott Laboratories - Key offerings

Exhibit 52: Abbott Laboratories - Segment focus

10.4 Akzo Nobel NV

Exhibit 53: Bausch Health Companies Inc. - Overview

Exhibit 54: Bausch Health Companies Inc. - Business segments

Exhibit 55: Bausch Health Companies Inc. - Key offerings

Exhibit 56: Bausch Health Companies Inc. - Segment focus

10.5 Zydus Lifesciences Ltd.

Exhibit 57: Zydus Lifesciences Ltd. - Overview

Exhibit 58: Zydus Lifesciences Ltd. - Business segments

Exhibit 59: Zydus Lifesciences Ltd. - Key offerings

Exhibit 60: Zydus Lifesciences Ltd. - Segment focus

10.6 Cipla Ltd.

Exhibit 61: Cipla Ltd. - Overview

Exhibit 62: Cipla Ltd. - Business segments

Exhibit 63: Cipla Ltd. - Key offerings

Exhibit 64: Cipla Ltd. - Segment focus

10.7 Eli Lilly and Co.

Exhibit 65: Eli Lilly and Co. - Overview

Exhibit 66: Eli Lilly and Co. - Business segments

Exhibit 67: Eli Lilly and Co. - Key offerings

Exhibit 68: Eli Lilly and Co. - Segment focus

10.8 Emcure Pharmaceuticals Ltd.

Exhibit 69: Emcure Pharmaceuticals Ltd. - Overview

Exhibit 70: Emcure Pharmaceuticals Ltd. - Product and service

Exhibit 71: Emcure Pharmaceuticals Ltd. - Key offerings

Exhibit 72: Emcure Pharmaceuticals Ltd. - Segment focus

10.9 GlaxoSmithKline Plc

Exhibit 73: GlaxoSmithKline Plc - Overview

Exhibit 74: GlaxoSmithKline Plc - Business segments

Exhibit 75: GlaxoSmithKline Plc - Key offerings

Exhibit 76: GlaxoSmithKline Plc - Segment focus

10.10 Maruho Co. Ltd.

Exhibit 77: Maruho Co. Ltd. - Overview

Exhibit 78: Maruho Co. Ltd. - Product and service

Exhibit 79: Maruho Co. Ltd. - Key offerings

10.11 Merck and Co. Inc.

Exhibit 80: Merck and Co. Inc. - Overview

Exhibit 81: Merck and Co. Inc. - Business segments

Exhibit 82: Merck and Co. Inc.- Key news

Exhibit 83: Merck and Co. Inc. - Key offerings

Exhibit 84: Merck and Co. Inc. - Segment focus

10.12 Novartis AG

Exhibit 85: Novartis AG - Overview

Exhibit 86: Novartis AG - Business segments

Exhibit 87: Novartis AG - Key offerings

Exhibit 88: Novartis AG - Segment focus

11. Appendix

11.1 Scope of the report

11.1.1 ????Market definition

11.1.2 ????Objectives

11.1.3 Notes and Caveats

11.2 Currency conversion rates for US$

Exhibit 89: ?Currency conversion rates for US$?

11.3 Research Methodology

Exhibit 90: ?Research Methodology

Exhibit 91: ??Validation techniques employed for market sizing?

Exhibit 92: ??Information sources

11.4 List of abbreviations

Exhibit 93: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

herpes zoster therapeutics market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis